Exagen (XGN) | Stock Overview & Key Data
Exagen Performance Comparison
Stock Range
Today's Range
52 Week Range
All-Time High: $29.86 on December 23, 2019
Explore how other US stocks compare to their 52-week ranges: View US Market 52-Week Insights
Key Statistics
Join Our United States Telegram Channel
Get Instant Market Updates: 52-Week High/Low Alerts, Breakout Notifications & Expert Stock Analysis Delivered To Your Phone. Join Traders Making Informed Decisions Daily!
Financial Highlights
Quarter Income Flow
Dec 31, 2025
Annual Income Flow
2025
Peer Performance Comparison
| Company | Market Cap | 1W | 1M | 3M | 6M | YTD | 1Y | 3Y | 5Y | 10Y | 15Y | 20Y |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
|
Exagen
XGN
|
64.46M Micro-cap | 8.81% | 25.55% | 44.62% | -34.99% | -24.34% | -34.41% | 43.69% | -70.12% | -72.53% | -72.53% | -72.53% |
|
Thermo Fisher
TMO
|
174.55B Large-cap | 0.87% | 8.07% | 0.79% | -17.74% | -20.05% | 16.53% | -12.65% | -2.72% | 220.94% | 654.32% | 1,231.84% |
|
Danaher
DHR
|
126.39B Large-cap | -1.32% | 11.85% | -5.38% | -20.75% | -21.40% | -10.25% | -15.98% | -20.94% | 174.08% | 416.93% | 738.84% |
| 221.68M Micro-cap | -3.42% | -48.59% | -48.44% | -44.42% | -55.49% | 124.28% | 243.60% | -68.44% | -65.12% | -65.12% | -65.12% | |
|
Fonar
FONR
|
118.64M Micro-cap | 0.42% | 0.90% | 3.19% | 32.02% | 3.08% | 31.75% | 8.10% | 6.11% | 6.89% | 915.43% | 73.55% |
|
Biodesix
BDSX
|
107.54M Micro-cap | 4.35% | 10.09% | -9.77% | 107.45% | 141.49% | 162.37% | -51.10% | -95.19% | -93.94% | -93.94% | -93.94% |
Ownership & Short Interest
Calculate Your Exagen Investment Returns
Long-Term Investment Performance Analysis
Exagen stock price in Sep 2019 was $17.00, A $1,000.00 lump sum investment in Exagen made 6 years ago would be worth approximately $268.82 today, representing a negative return of -73.12%. This translates to an annualized return (CAGR) of -17.69%.
6 Years 8 Months Investment Scenario (Sep 2019 - Jun 2026)
Investment Breakdown
Value Comparison
Disclaimer: This calculator is for informational purposes only and does not consider taxes, fees, or other costs associated with investing. Past performance does not guarantee future results.
Frequently Asked Questions
- What is XGN's 52-week high and low?
- In the last 52 weeks, Exagen reached a high of $12.23 (on October 27, 2025) and a low of $2.59 (on March 30, 2026).
- What is the market cap and P/E ratio for XGN?
- Curious about Exagen's size and valuation? Its market capitalization stands at 64.46M. When it comes to valuation, the P/E ratio (trailing twelve months) is N/A, and the forward P/E (looking ahead) is -5.96.
- Does XGN pay dividends? If so, what's the yield?
- As for dividends, Exagen isn't currently offering a significant yield, or that specific data isn't available right now.
- Who are Exagen's main competitors or similar companies to consider before investing?
When looking at Exagen, it can be helpful to see how it compares to other players in its field. Here are a few similar companies or key competitors:
Company Mkt Cap Sector Industry 1Y Return 3Y Return Thermo Fisher
TMO174.55B Healthcare Diagnostics & Research 16.53% -12.65% Danaher
DHR126.39B Healthcare Diagnostics & Research -10.25% -15.98% Burning Rock Biotech
BNR221.68M Healthcare Diagnostics & Research 124.28% 243.60% Fonar
FONR118.64M Healthcare Diagnostics & Research 31.75% 8.10% Biodesix
BDSX107.54M Healthcare Diagnostics & Research 162.37% -51.10% For a more comprehensive list, please see the Peer Performance Comparison table on this page.
- What are the key financial health indicators for Exagen Inc.? (e.g., ROE, Debt/Equity)
- To get a sense of Exagen's financial health, here are a few key indicators: its Return on Equity (ROE) over the last twelve months is -147.85%, the Debt to Equity ratio from the most recent quarter is 158.55, and its Gross Profit Margin stands at 55.35%.
- What is the recent revenue and earnings growth for XGN?
- Looking at Exagen's growth, its revenue over the trailing twelve months (TTM) was $67M. Compared to the same quarter last year (YoY), quarterly revenue grew by 21.80%, and quarterly earnings saw a YoY growth of 21.79%.
- How much of XGN stock is held by insiders and institutions?
- Wondering who owns Exagen stock? Company insiders (like executives and directors) hold about 18.09% of the shares, while institutional investors (such as mutual funds and pension funds) own approximately 59.71%.
For more common questions about our data, please visit our About Data page.
Data is provided for informational purposes only. Devyara does not guarantee the accuracy of the data displayed.